Publication Name	World Journal of Hepatology
Manuscript ID	13884
Country	Italy

Received	2014-09-05 18:13
Peer-Review Started	2014-09-06 17:43
To Make the First Decision	2014-09-28 12:31
Return for Revision	2014-10-06 17:12
Revised	2014-10-16 22:49
Second Decision	2015-02-04 11:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-02-11 15:21
Articles in Press	2015-02-11 15:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-29 16:54
Publish the Manuscript Online	2015-05-20 16:43

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Intermediate hepatocellular carcinoma: How to choose the best treatment modality?
Manuscript Source	Invited Manuscript
All Author List	Giovan Giuseppe Di Costanzo and Raffaella Tortora
Funding Agency and Grant Number
Corresponding Author	Giovan Giuseppe Di Costanzo, Depart­ment of Transplantation, Liver Unit, Cardarelli Hospital, Via A Cardarelli 9, 80131, Naples, Italy. ggdicostanzo@libero.it
Key Words	Hepatocellular carcinoma; Percutaneous ablation; Hepatectomy; Chemoembolization; Liver transplantation; Combination therapy
Core Tip	Intermediate stage, or stage B according to Barcelona Clinic Liver Cancer classification, of hepatocellular carcinoma (HCC) comprises a hetero-geneous population with different tumor burden and liver function. This heterogeneity is confirmed by the large variability in treatment and survival, the choice of the best treatment in the patient with intermediate stage HCC is a difficult task. A multisciplinary evaluation of each intermediate stage HCC patient is recommended for planning the best therapeutic strategy and this review was aimed to discuss about the existing evidences regarding this topic. Due to the heterogeneity of intermediate HCC, the use of different therapies (combination treatment) is likely the best choice in most of the cases offering the opportunity of a treatment tailored to the single patient.
Publish Date	2015-05-20 16:43
Citation	Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191
URL	http://www.wjgnet.com/1948-5182/full/v7/i9/1184.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i9.1184

Full Article (PDF)	WJH-7-1184.pdf
Full Article (Word)	WJH-7-1184.doc
Manuscript File	13884-Review.doc
Answering Reviewers	13884-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13884-Conflict-of-interest statement.pdf
Copyright License Agreement	13884-Copyright assignment.pdf
Peer-review Report	13884-Peer-review(s).pdf
Scientific Misconduct Check	13884-Scientific misconduct check.pdf
Scientific Editor Work List	13884-Scientific editor work list.pdf